Table 1.

Characteristics of Study Population

Parameter	Imatinib 400 mg [n=50]	Imatinib 800 mg [n=209]
Median age, y (range)	47 (15-79)	51 (17-84)
Male sex, No. (%)	26 (52)	83 (40)
Hemoglobin (g/L), median (range)	12.5 (7.9-15)	12.2 (6.2-16.7)
Neutrophil (×109/L), median (range)	15.5 (0.5-158)	19.2 (0-164)
Platelet (×109/L), median (range)	433 (139-1043)	420 (58-1476)
Splenomegaly, No. (%)	11 (22)	60 (29)
Median follow-up, mo (range)	84 (2-90)	59 (4-85)
Sokal risk score, No. (%)
Low	33 (66)	132 (63)
Intermediate	15 (30)	58 (28)
High	2 (4)	19(9)
Renal function, No. (%)
Normal	46 (92)	202 (97)
Mild	4 (8)	5 (3)
Moderate	0 (0)	2 (1)
Severe	0 (0)	0 (0)
Liver function, No. (%)
Normal	43 (86)	178 (84)
Mild	7 (14)	31 (16)
Moderate	0 (0)	0 (0)
Severe	0 (0)	0 (0)